• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'

    3/11/26 11:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual 'Abbott Dream Team'
    • All participants will receive sports nutrition guidance from Abbott experts and take part in on-field development sessions led by Real Madrid coaches
    • The 16 selected male and female 'Abbott Dream Team' members, ages 18–19, will travel to Spain on an all‑expenses‑paid trip to train at Real Madrid's official facilities
    • Learn more and register at AbbottDreamTeam.com

    ABBOTT PARK, Ill., March 11, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18–19 across the United States to sign up for the chance to take part in a once-in-a-lifetime development experience in Madrid. Selected participants will train with Real Madrid's world‑renowned coaches at the club's facilities and enjoy unique opportunities, including attending a Real Madrid match at the Bernabéu Stadium and meeting club legends. Building on the success of last year's inaugural program, the initiative once again aims to help promising athletes strengthen their skills, knowledge and confidence on and off the pitch.

    Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team'

    As part of the experience, Abbott health experts and Real Madrid's medical team will continue providing participants with the latest advancements in sports health and nutrition – helping them better understand their bodies, build healthier habits, and reach peak performance.

    Following their training in Madrid, this year's 'Abbott Dream Team' will return home to lead health and nutrition sessions with Abbott at local soccer and youth organizations, inspiring even more young players to embrace healthy habits and pursue their potential.

    To share invaluable perspective on the qualities needed to sustain success on the field, legendary Real Madrid player Marcelo will join this year's 'Abbott Dream Team' as a mentor.

    "During my years at Real Madrid, I benefited from world‑class nutrition and health guidance," Marcelo said. "Young players can't reach their full potential without a strong nutritional foundation, and I'm excited to work with Abbott to help the next generation build the habits and skills that fueled my career."

    'Abbott Dream Team' Selection Events

    All selection event participants will engage in dynamic soccer development sessions led by Real Madrid coaches and receive health and nutrition education from Abbott. Attendees will receive an 'Abbott Dream Team' adidas jersey and an Abbott health toolkit. Space is limited per event, and athletes must provide proof of age. Participants will receive a confirmation notice following registration.

    Athletes can learn more and register at AbbottDreamTeam.com. Selection events will take place at the following locations and dates:

    • Miami: Tuesday, May 19
      • AutoNation Field (7620 SW 36th St, Davie, FL 33314)
    • Washington, D.C.: Thursday, May 21
      • Howard University (Girard St & 6th St NW, Washington, DC 20059)
    • Houston: Wednesday, May 27
      • South Houston High School (3820 Shaver St, South Houston, TX 77587)
    • Kansas City: Tuesday, June 2
      • Shawnee Mission Soccer Complex (9300 Nieman Rd, Overland Park, KS 66214)
    • Los Angeles: Thursday, June 4
      • California State University, Los Angeles (22 Circle Dr, Los Angeles, CA 90032)
    • Chicago: Tuesday, June 9
      • Intentional Sports (1841 N Laramie Ave, Chicago, IL 60639)

    The 'Abbott Dream Team' Madrid Experience

    Following the nationwide selection events, 16 players will be picked for their teamwork, soccer skills, leadership, and growth mindset and sent on an all‑expenses‑paid trip to Madrid for an unforgettable experience. Members of the final roster will train with Real Madrid coaches at the club's renowned facilities, attend a match at the iconic Bernabéu Stadium, meet club legends and learn about the latest advancements in sports science from Abbott nutritionists and Real Madrid's medical team.

    Inspiring Health, Performance and Potential

    Following their trip to Madrid, 'Abbott Dream Team' members will have the opportunity to share their knowledge and help promote the benefits of living a healthy lifestyle within their local communities by collaborating with Abbott to participate in health training events at local soccer and youth organizations.

    "Following a successful first year, we're excited to bring back the 'Abbott Dream Team' and continue empowering young athletes through the power of nutrition and sport," said Melissa Brotz, chief marketing, communications and sustainability officer, Abbott. "Good health is critical to success on and off the pitch, and this program gives players lifelong tools they can carry with them well beyond their athletic careers. Our partnership with Real Madrid and the Dream Team program reflects that shared commitment."

    As the Global Health Sciences and Nutrition Partner of the Real Madrid Football Club, Abbott provides nutritional guidance for Real Madrid's first men's and women's and Academy teams through research-based dietary recommendations backed by the company's over 135-year heritage in health sciences and understanding of the needs of athletes.

    The 'Abbott Dream Team' program is a youth development and educational initiative and is not affiliated with player recruitment or talent scouting for Real Madrid C.F.

    About Abbott

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook,  Instagram,  X and YouTube.

    About Real Madrid C.F.

    Real Madrid C.F. is a sport entity with 124 years of history. It is the club with the most European Cups of both football (15) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 660 million followers on social media, being the strongest football brand in the world according to Brand Finance for the fourth year in a row and also the highest earning football club in the world in the 24-25 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year.

     

    Abbott Logo (PRNewsfoto/Abbott)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team-302710649.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Shroff Eric covered exercise/tax liability with 1,384 units of Common shares without par value and sold $81,946 worth of Common shares without par value (709 units at $115.58), decreasing direct ownership by 5% to 39,164 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    3/3/26 8:20:08 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXECUTIVE VICE PRESIDENT Scoggins Christopher J covered exercise/tax liability with 4,997 units of Common shares without par value, decreasing direct ownership by 6% to 77,126 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    3/3/26 8:15:27 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP AND GROUP PRESIDENT Salvadori Daniel Gesua Sive covered exercise/tax liability with 6,615 units of Common shares without par value and sold $102,288 worth of Common shares without par value (885 units at $115.58), decreasing direct ownership by 5% to 146,377 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    3/3/26 8:10:48 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'

    Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual 'Abbott Dream Team'All participants will receive sports nutrition guidance from Abbott experts and take part in on-field development sessions led by Real Madrid coachesThe 16 selected male and female 'Abbott Dream Team' members, ages 18–19, will travel to Spain on an all‑expenses‑paid trip to train at Real Madrid's official facilitiesLearn more and register at AbbottDreamTeam.comABBOTT PARK, Ill., March 11, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players

    3/11/26 11:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exact Sciences Stockholders Approve Acquisition by Abbott

    Exact Sciences Corporation (NASDAQ:EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE:ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date for the special meeting, were voted in favor of the transaction. Final voting results from the special meeting will be reported by Exact Sciences in a Current Report on Form 8‑

    2/20/26 4:05:00 PM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    3/9/26 4:21:32 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    2/26/26 4:16:53 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Abbott Laboratories

    424B5 - ABBOTT LABORATORIES (0000001800) (Filer)

    2/25/26 7:01:49 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

    Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpointABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025. Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-re

    1/22/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for fourth-quarter earnings

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    1/5/26 4:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care